Exacis Biotherapeutics is using mRNA to reprogram somatic cells to create induced pluripotent stem cells (iPSCs) in-house. We further engineer these high quality iPSCs using mRNA to vectorize our proprietary gene editing protein NoveSlice™ to create engineered iPSCs that are allogeneic, potent and safe. We then differentiate these cells into highly active engineered iNK cells for treatment of malignancies with high unmet medical needs.
Exacis is democratizing access to cell therapies for cancer treatment by employing non-viral, capital-efficient manufacturing processes to decrease the cost of treatment while at the same time improving the safety of cell therapies. Exacis has exclusively in-licensed a robust portfolio of patents for producing engineered NK and T cells for oncology. The technology is applied to generate a programmable therapeutics platform that can be modified, using our in-licensed library of gene editing protein building blocks, to target virtually any cancer antigen. We plan to treat both solid and hematologic tumors with a goal to improve the patient experience while improving outcomes and decreasing the cost of care.